,

Pitawin EZ

Composition:

  • Pitavastatin Calcium equivalent to Pitavastatin 2 mg

  • Ezetimibe IP 10 mg
    Therapeutic Class:

  • Statin + Cholesterol Absorption Inhibitor
    Schedule: Schedule H (Prescription Only)

Pitawin EZ combines the power of Pitavastatin, a next-generation statin, with Ezetimibe, a cholesterol absorption inhibitor, offering dual lipid-lowering action. This combination is especially effective in patients not adequately controlled on statin monotherapy or those needing aggressive LDL-C reduction with lower statin doses.

Usage of Pitawin EZ

Pitawin EZ is indicated for:

  • Primary hypercholesterolemia (familial or non-familial)

  • Mixed dyslipidemia

  • Patients with diabetes, metabolic syndrome, or statin intolerance

  • High-risk or very high-risk cardiovascular patients requiring intensive lipid control

  • As an adjunct to diet, lifestyle changes, and other lipid-lowering therapies


Mechanism of Action

🔹 Pitavastatin (2 mg)

  • Inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis

  • Increases LDL receptor expression → enhanced LDL clearance

  • Also increases HDL-C, improves TG profile, and enhances insulin sensitivity

🔹 Ezetimibe (10 mg)

  • Selectively blocks NPC1L1 transporter in the small intestine

  • Inhibits dietary and biliary cholesterol absorption

  • Complements statin effect by reducing cholesterol influx to liver

Together, they deliver synergistic LDL-C reduction via dual blockade:

  • Synthesis + Absorption inhibition


Key Benefits

✅ ~55–60% LDL-C reduction (additive effect)
✅ Effective in statin-intolerant or low-dose statin candidates
✅ Raises HDL, improves atherogenic index (AI)
✅ Better TG control and insulin-friendly profile with Pitavastatin
✅ Reduced risk of hepatic enzyme elevation and myopathy vs. high-dose statins


Common Side Effects

  • Headache, abdominal pain

  • Mild muscle aches (rare)

  • Flatulence, nausea

  • Transient elevations in liver enzymes or CPK (infrequent)


Precautions

  • Not for use in active liver disease or unexplained elevated liver enzymes

  • Monitor LFTs and lipid profile periodically

  • Avoid alcohol consumption during therapy

  • Use with caution in elderly and patients with renal impairment

  • Contraindicated in pregnancy and lactation


Drug Interactions

  • Avoid concomitant use with strong CYP3A4 inhibitors (e.g., cyclosporine, gemfibrozil)

  • May enhance effect of oral anticoagulants (e.g., warfarin)

  • Safe with antidiabetics and antihypertensives

  • Separate dosing from bile acid sequestrants (if used)


Dosage and Administration

  • One tablet once daily, with or without food

  • Administer at same time each day, preferably in the evening

  • Dietary fat reduction enhances efficacy


Storage

  • Store below 25°C, away from moisture and sunlight

  • Keep out of reach of children


Patient Counseling Points

  • Follow a low-fat, heart-healthy diet

  • Report muscle pain, weakness, or jaundice

  • Avoid grapefruit juice

  • Do not stop therapy without consulting physician

  • Regular lipid and liver monitoring is essential

Review My Order

0

Subtotal